AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14727868
Drug: Liposomal tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal tretinoin (TRE) and benzoyl peroxide (BP) gels
Trial: 8070509
Drug: Oral lomefloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lomefloxacin 200 mg with furosemide 40 mg
Trial: 8070509
Drug: Oral lomefloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lomefloxacin 200 mg alone
Trial: 8070509
Drug: Furosemide 40
RxNorm normalized name: furosemide 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide 40 mg alone
Trial: 3123119
Drug: Complete intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete intravenous nutritional support (IVF) with all D‐glucose
Trial: 3123119
Drug: Complete intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete intravenous nutritional support (IVF) with 50% D‐glucose/50% lipid
Trial: 3123119
Drug: Complete intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete intravenous nutritional support (IVF) with D‐glucose/amino acid regimen
Trial: 3123119
Drug: Complete intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete intravenous nutritional support (IVF) with D‐glucose/lipid/amino acid regimen
Trial: 20406831
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy (NT) including epirubicin/cyclophosphamide followed by docetaxel alone, docetaxel with capecitabine, or docetaxel followed by capecitabine, with additional trastuzumab treatment for HER2-positive tumors.
Trial: 20406831
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy (NT) with trastuzumab for HER2-positive tumors.
Trial: 20406831
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy (NT) with no specific control mentioned.
Trial: 18242480
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with carvedilol and amiodarone
Trial: 2903425
Drug: CV 205‐502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CV 205‐502 (0.01 to 0.09 mg single oral doses)
Trial: 2903425
Drug: CV 205‐502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CV 205‐502 (0.06 mg single oral dose)
Trial: 26573323
Drug: Motivational Enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Enhancement Treatment (MET)
Trial: 26573323
Drug: Compliance with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compliance with treatment (secondary outcome)
Trial: 19638080
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (nadolol plus isosorbide‐5‐mononitrate)
Trial: 19638080
Drug: Combined group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined group (banding ligation plus medications)
Trial: 15108863
Drug: 2% clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% clindamycin vaginal cream (CVC)
Trial: 11117277
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day of lycopene (LYC‐O‐MATO)
Trial: 9494599
Drug: ABVD chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABVD chemotherapy followed by mediastinal irradiation at a median dose of 36 Gy (range 30.6‐43.2)
Trial: 30011303
Drug: Complementary and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary and alternative medicine (CAM) usage
Trial: 25944813
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg dexketoprofen in 50 ml saline
Trial: 25944813
Drug: 50 ml
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ml saline as placebo
Trial: 23206408
Drug: Low-dose Cyclosporine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Cyclosporine A (trough concentrations 130 < CsA < 200 μg/L, n=47)
Trial: 23206408
Drug: Standard-dose Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose Cyclosporine A (trough concentrations 200 < CsA < 300 μg/L, n=48)
Trial: 18608200
Drug: Valsartan vs
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan vs Amlodipine (Treatment Benefit)
Trial: 10903213
Drug: Cylexin (CY-1503)
RxNorm normalized name: Cys
DrugBank: Cysteine (DB00151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cylexin (CY-1503) administered on the day of surgery
Trial: 9071250
Drug: Telephone-based problem-solving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-based problem-solving therapy sessions conducted by graduate student therapists supervised by a psychiatrist.
Trial: 24356922
Drug: Oral oxycodone
RxNorm normalized name: oxycodone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oxycodone plus intravenous acetaminophen
Trial: 24356922
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine sulfate
Trial: 23042034
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin (onabotulinumtoxinA) injection (160 U) into biceps brachii
Trial: 23042034
Drug: Before injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before injection
Trial: 19503784
Drug: Degarelix (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Degarelix (240 mg initial dose followed by 80 mg or 160 mg monthly injections)
Trial: 28427285
Drug: Leuprolide (GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide (GnRH agonist)
Trial: 11220888
Drug: Quadropril (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadropril (6 mg once daily)
Trial: 11220888
Drug: Amlodipine (initially
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (initially 5 mg/day, increased to 10 mg/day if necessary)
Trial: 9750602
Drug: Intramuscular ephedrine
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular ephedrine 30 mg immediately after SB
Trial: 9750602
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 mL of intramuscular saline) immediately after SB
Trial: 8458358
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (Nifedipine + Propranolol)
Trial: 3797826
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of oral nifedipine
Trial: 14584565
Drug: FDG uptake
RxNorm normalized name: (18F)-FDG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDG uptake ratios with occipital lobe metabolism as covariate reference region
Trial: 14584565
Drug: FDG uptake
RxNorm normalized name: (18F)-FDG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDG uptake ratios with white matter metabolism as reference covariate
Trial: 10712324
Drug: Intravenous augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous augmentation therapy
Trial: 8689423
Drug: Low-dose cytosine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cytosine arabinoside (LD AraC) 2 x 10 mg/m2 sc, day 1-14 plus interleukin-3 (IL-3) once daily sc, day 8-21 at varying doses (1.0, 2.5, 5.0, and 10.0 micrograms/kg)
Trial: 31856049
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (placebo group)
Trial: 29137628
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline (HS) pre-injection 4 mL/kg 7.5% HS
Trial: 29137628
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline (HS) pre-injection
Trial: 29137628
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (NS group) pre-injection 4 mL/kg isotonic saline
Trial: 26637580
Drug: Long-term low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Long-term low-dose azithromycin (250 mg daily for 3 months) plus standard conventional treatment (fluticasone nasal spray plus normal saline solution irrigation)
Trial: 26637580
Drug: Standard conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard conventional treatment (fluticasone nasal spray plus normal saline solution irrigation)
Trial: 24924416
Drug: Fulvestrant (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulvestrant (500 mg IM days 1, 15, 29, then monthly) plus Vandetanib (100 mg PO OD)
Trial: 24924416
Drug: Fulvestrant (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulvestrant (500 mg IM days 1, 15, 29, then monthly) plus Placebo
Trial: 19463034
Drug: Group music
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group music therapy (10-week project with ten one-hour weekly sessions including song singing, song writing, and improvisation)
Trial: 23639952
Drug: Group music
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group music therapy
Trial: 16131696
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg caffeine . kg(‐1) . d(‐1) (C3)
Trial: 16131696
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg caffeine . kg(‐1) . d(‐1) (C6)
Trial: 16131696
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg caffeine . kg(‐1) . d(‐1) (C0; placebo)
Trial: 9987086
Drug: Low-protein diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein diet (LPD) 0.6 g.kg-1.24 hr-1, N = 14
Trial: 7591421
Drug: Simple silicone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple silicone gel sheets
Trial: 7427409
Drug: Indomethacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (100 mg daily for three weeks) with Propranolol
Trial: 7427409
Drug: Indomethacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (100 mg daily for three weeks) with Thiazide diuretics
Trial: 7427409
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with Thiazide diuretics
Trial: 30803290
Drug: Intraoperative plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative plus postoperative hemoadsorption therapy
Trial: 30803290
Drug: Sole intraoperative
RxNorm normalized name: English sole
DrugBank: English sole (DB10904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sole intraoperative hemoadsorption therapy
Trial: 29280118
Drug: Microecological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microecological treatment group
Trial: 25902320
Drug: Remifentanil 1
RxNorm normalized name: remifentanil 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 1 ng•mL with propofol TCI between 2.40 and 4.23 μg•mL (bolus of 1 mg•kg)
Trial: 25902320
Drug: Remifentanil 2
RxNorm normalized name: remifentanil 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 2 ng•mL with propofol TCI between 2.15 and 2.88 μg•mL (bolus of 0.75 mg•kg)
Trial: 25902320
Drug: Propofol fixed
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol fixed at 2 μg•mL with remifentanil TCI between 1.00 to 4.79 ng•mL
Trial: 25902320
Drug: Propofol fixed
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol fixed at 3 μg•mL with remifentanil TCI between 0.72 to 3.19 ng•mL
Trial: 21131862
Drug: One-third maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-third maintenance dose of resistance training
Trial: 21131862
Drug: One-ninth maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-ninth maintenance dose of resistance training
Trial: 19750261
Drug: Aspirin (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (1.5 g/day, 500 mg every 8 hours)
Trial: 19799843
Drug: Virosomal vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virosomal vaccine
Trial: 12553505
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg meloxicam
Trial: 29476542
Drug: Emollient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emollient treatment (specific emollients not detailed)
Trial: 12055813
Drug: Nitazoxanide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitazoxanide (100 mg for age 1-3 years or 200 mg for age 4-11 years, twice daily for 3 days)
Trial: 12055813
Drug: Praziquantel (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel (25 mg/kg single dose)
Trial: 10480704
Drug: Non-fasting serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-fasting serum true insulin concentration
Trial: 10480704
Drug: Non-fasting serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-fasting serum glucose > or =6.1 mmol/l at baseline
Trial: 8983443
Drug: D‐dimer level
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D‐dimer level detected using semiquantitative method (D‐dimer Latex Test, Diagnostica Stago‐Boehringer Mannheim) before and during treatment.
Trial: 8983443
Drug: Cells number
RxNorm normalized name: Derma Numb
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cells number and composition using light microscope before and during treatment.
Trial: 8983443
Drug: D‐dimer level
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D‐dimer level in tuberculous effusions before treatment.
Trial: 1765040
Drug: Moderate-dose fentanyl
RxNorm normalized name: fentanyl Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-dose fentanyl (20 micrograms kg-1) combined with isoflurane, nitrous oxide and oxygen
Trial: 6604371
Drug: Neodymium-Yag laser
RxNorm normalized name: Neodymium
DrugBank: Neodymium (DB15318)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neodymium-Yag laser treatment
Trial: 22769569
Drug: UFT adjuvant
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT adjuvant therapy (500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by 2-day rest, repeated for 1 year)
Trial: 22769569
Drug: UFT adjuvant
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT adjuvant therapy
Trial: 22769569
Drug: Observation without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Observation without any adjuvant treatment
Trial: 15933481
Drug: Long-acting risperidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting risperidone (25, 50 or 75 mg every 2 weeks)
Trial: 8783991
Drug: Aprotinin (full
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (full recommended dose) in group D
Trial: 1474275
Drug: BCG 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG 0.1 mg + 6 x 10(8) KML (I)
Trial: 1474275
Drug: BCG 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG 0.1 mg + 5 x 10(7) KML (II)
Trial: 1474275
Drug: BCG 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG 0.1 mg + 5 x 10(6) KML (III)
Trial: 1474275
Drug: BCG 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG 0.1 mg (IV)
Trial: 6204413
Drug: Control (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (3 mg/kg heparin)
Trial: 6204413
Drug: Prostacyclin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostacyclin infusion before CPB
Trial: 24825343
Drug: Pre-dialysis heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-dialysis heparin coating of the membrane
Trial: 24825343
Drug: Constant saline
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant saline infusion
Trial: 21105281
Drug: Risperidone at
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone at 6 mg/d plus buspirone at 60 mg/d
Trial: 21105281
Drug: Risperidone at
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone at 6 mg/d plus placebo
Trial: 12842375
Drug: Oral opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral opioid analgesia
Trial: 10658520
Drug: Carboplatin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (200 mg/m2) and cisplatin (60 mg/m2) with ifosfamide
Trial: 10658520
Drug: Carboplatin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (200 mg/m2) and cisplatin (60 mg/m2) without ifosfamide
Trial: 6652010
Drug: Morphine 10
RxNorm normalized name: morphine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 10 mg i.m.
Trial: 8889289
Drug: ACET/COD combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACET/COD combination
Trial: 3330115
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg tid)
Trial: 6209500
Drug: Metformin (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (after placebo)
Trial: 6209500
Drug: Metformin (during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (during treatment)
Trial: 31603076
Drug: Transcutaneous Vagal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous Vagal Nerve Stimulation (t-VNS) using GammaCore device for 2 weeks, self-administered three times per day.
Trial: 31603076
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment for 2 weeks, self-administered three times per day.
Trial: 28852716
Drug: Dry cupping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry cupping therapy on the abdominal wall for 8 minutes every other day for 4 weeks
Trial: 28852716
Drug: Standard laxative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard laxative therapy (Polyethylene glycol (PEG) 40% solution without electrolyte), 0.4 g/kg once daily for 4 weeks
Trial: 28852716
Drug: Standard laxative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard laxative therapy
Trial: 17623805
Drug: meat-sweet dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meat-sweet dietary pattern (4th quartile) in postmenopausal women with estrogen receptor-positive tumors
Trial: 8513736
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline solution (1.5 mmols and above)
Trial: 23608794
Drug: Golden Bifid
RxNorm normalized name: GOLDEN SEAL
DrugBank: Goldenseal (DB16594)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golden Bifid 2.0 g, bid for 24 months
Trial: 23608794
Drug: Changmei 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changmei 1.0 g, tid for 24 months
Trial: 23608794
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Golden Bifid and Changmei for 24 months
Trial: 15204012
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg xaliproden
Trial: 9824789
Drug: piperacillin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: piperacillin (4 g) plus ciprofloxacin (400 mg)
Trial: 9824789
Drug: piperacillin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: piperacillin (4 g) plus tazobactam (0.5 g)
Trial: 9824789
Drug: piperacillin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: piperacillin (4 g)
Trial: 9824789
Drug: ciprofloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ciprofloxacin (400 mg)
Trial: 25812179
Drug: Increased oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased oral lingual pressure during swallowing
Trial: 21907600
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (81 mg · day(‐1))
Trial: 21907600
Drug: High-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose aspirin (650 mg · day(‐1))
Trial: 21907600
Drug: Placebo (cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (cellulose capsule)
Trial: 19184028
Drug: Raj yoga
RxNorm normalized name: drospirenone
DrugBank: Drospirenone (DB01395)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Raj yoga program (bi-weekly for 12 sessions)
Trial: 15978307
Drug: Flurbiprofen axetil
RxNorm normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen axetil 25 mg